{"id":616077,"date":"2022-09-13T19:26:01","date_gmt":"2022-09-13T19:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=616077"},"modified":"2022-09-13T19:26:01","modified_gmt":"2022-09-13T19:26:01","slug":"generalized-anxiety-disorder-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-takeda-astrazeneca-eli-lilly-and-company-forest-laboratories","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/generalized-anxiety-disorder-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-takeda-astrazeneca-eli-lilly-and-company-forest-laboratories_616077.html","title":{"rendered":"Generalized Anxiety Disorder Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies &#8211; Takeda, AstraZeneca, Eli Lilly and Company, Forest Laboratories"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1663070899.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Generalized Anxiety Disorder Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - Takeda, AstraZeneca, Eli Lilly and Company, Forest Laboratories\" src=\"https:\/\/www.abnewswire.com\/uploads\/1663070899.jpeg\" alt=\"Generalized Anxiety Disorder Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - Takeda, AstraZeneca, Eli Lilly and Company, Forest Laboratories\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cGeneralized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Generalized Anxiety Disorder, historical and forecasted epidemiology as well as the Generalized Anxiety Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">The <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/generalized-anxiety-disorder-gad-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Generalized Anxiety Disorder market<\/a> is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Generalized Anxiety Disorder pipeline products will significantly revolutionize the Generalized Anxiety Disorder market dynamics.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Generalized Anxiety Disorder Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Generalized anxiety disorder (GAD) is recognized as the most common anxiety disorder within primary care, carrying a significant degree of comorbidity, impairment, and disability. GAD is characterized by a chronic, persistent pattern of worrying, anxiety symptoms, and tension that has a waxing and waning course, often without full remission.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The criteria of Generalized anxiety disorder in DSM-V include the characteristics such as feeling restless, keyed up, or on edge, fatiguing easily, difficulty concentrating or the mind going blank, irritability, increased muscle tension, difficulty falling asleep, staying asleep, or restlessness.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Generalized Anxiety Disorder Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Generalized Anxiety Disorder market size is anticipated to grow with a significant CAGR during the study period (2019-2032)&nbsp;&nbsp;<\/li>\n<li>Anxiety is the most common mental disorder in the United States, affecting approximately 40 million adults&nbsp;<\/li>\n<li>The majority of adults with anxiety have a mild impairment (43.5%), 33.7% have a moderate impairment, and 22.8% have a serious impairment&nbsp;<\/li>\n<li>Anxiety disorders are more common in females than in males. Anxiety affects 23% of female adults and<\/li>\n<li>14% of male adults&nbsp;<\/li>\n<li>Generalized Anxiety Disorder is often unrecognized or misdiagnosed as a physical condition due to the range of clinical presentations, including somatic symptoms, and the frequent occurrence of comorbid conditions&nbsp;<\/li>\n<li>Key Generalized Anxiety Disorder Companies: Takeda, AstraZeneca, Eli Lilly and Company, Forest Laboratories, Sage Therapeutics, Biohaven Pharmaceuticals, Fabre-Kramer Pharmaceuticals, and others&nbsp;<\/li>\n<li>Key Generalized Anxiety Disorder Therapies: Vortioxetine, Duloxetine, Troriluzole, Vilazodone, Quetiapine fumarate, and others&nbsp;<\/li>\n<li>The Generalized Anxiety Disorder epidemiology based on gender analyzed that Generalized anxiety disorder (GAD) is more prevalent in females than males<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download a Free sample for the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/generalized-anxiety-disorder-gad-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Generalized Anxiety Disorder Market Report<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the Generalized Anxiety Disorder Market report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Generalized Anxiety Disorder market report covers a descriptive overview and comprehensive insight of the Generalized Anxiety Disorder Epidemiology and Generalized Anxiety Disorder market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Generalized Anxiety Disorder market report provides insights on the current and emerging therapies.<\/li>\n<li>Generalized Anxiety Disorder market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Generalized Anxiety Disorder market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Generalized Anxiety Disorder market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Generalized Anxiety Disorder market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/generalized-anxiety-disorder-gad-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Generalized Anxiety Disorder market forecast<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Generalized Anxiety Disorder Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Generalized Anxiety Disorder market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Generalized Anxiety Disorder<\/li>\n<li>Prevalent Cases of Generalized Anxiety Disorder by severity<\/li>\n<li>Gender-specific Prevalence of Generalized Anxiety Disorder<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Generalized Anxiety Disorder&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Generalized Anxiety Disorder Market &nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Generalized Anxiety Disorder market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as EXXUA, SAGE-217, and others during the forecasted period 2019-2032.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&ldquo;Currently, only a few companies are actively involved in the development of Generalized anxiety disorder therapies, however, considering the disease burden associated with Generalized anxiety disorder, there is a dire need of novel therapies to cater the patient needs.&rdquo;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Generalized Anxiety Disorder epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/generalized-anxiety-disorder-gad-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Generalized Anxiety Disorder Epidemiological Insights<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Generalized Anxiety Disorder Market Strengths<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Generalized anxiety disorder (GAD)&nbsp;<\/li>\n<li>Newborn screening for Generalized anxiety disorder (GAD) has been implemented in several countries, enabling the early detection of individuals with Fabry mutations&nbsp;<\/li>\n<li>Many therapies are under investigation in various phases of clinical trials. These include pegylated forms of &alpha;-GAL, gene therapy, and substrate reduction therapy&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Generalized Anxiety Disorder Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Vortioxetine:<\/strong> Takeda<\/li>\n<li><strong>Duloxetine:<\/strong> AstraZeneca<\/li>\n<li><strong>Troriluzole:<\/strong> Eli Lilly and Company<\/li>\n<li><strong>Vilazodone:<\/strong> Forest Laboratories<\/li>\n<li><strong>Quetiapine fumarate:<\/strong> Sage Therapeutics, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Generalized Anxiety Disorder Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Study Period: 2019&ndash;2032<\/li>\n<li>Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li>Key Generalized Anxiety Disorder Companies: Takeda, AstraZeneca, Eli Lilly and Company, Forest Laboratories, Sage Therapeutics, Biohaven Pharmaceuticals, Fabre-Kramer Pharmaceuticals, and others<\/li>\n<li>Key Generalized Anxiety Disorder Therapies: Vortioxetine, Duloxetine, Troriluzole, Vilazodone, Quetiapine fumarate, and others<\/li>\n<li>Therapeutic Assessment: Generalized Anxiety Disorder current marketed and Generalized Anxiety Disorder emerging therapies<\/li>\n<li>Generalized Anxiety Disorder Market Dynamics:&nbsp; Generalized Anxiety Disorder market drivers and barriers&nbsp;<\/li>\n<li>Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li>Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Generalized Anxiety Disorder&nbsp; Market Access and Reimbursement&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Generalized Anxiety Disorder Market Opportunities&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Development of a potential biomarker that allows for tracking and predicting the severity and potential progress of the disease and the effectiveness of any therapeutic intervention&nbsp;<\/li>\n<li>Relative lack of enzyme replacement therapy efficacy, partly due to antibody formation, can be alleviated by combining new oral therapy approaches&nbsp;<\/li>\n<li>Due to patients&#8217; poor quality of life with Generalized anxiety disorder (GAD), there is significant patient willingness towards expensive therapies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Generalized Anxiety Disorder Market Unmet Needs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Challenges in diagnoses<\/li>\n<li>Development of novel Generalized Anxiety Disorder therapies<\/li>\n<li>Limitations in gene therapy&nbsp;<\/li>\n<li>Poor disease understanding&nbsp;<\/li>\n<li>Clinical biomarkers&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Generalized Anxiety Disorder Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Generalized Anxiety Disorder<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Generalized Anxiety Disorder<\/p>\n<p style=\"text-align: justify;\">4. Generalized Anxiety Disorder Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Generalized Anxiety Disorder Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Generalized Anxiety Disorder Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Generalized Anxiety Disorder Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Generalized Anxiety Disorder&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Generalized Anxiety Disorder Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Generalized Anxiety Disorder Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Generalized Anxiety Disorder Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Generalized Anxiety Disorder Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Generalized Anxiety Disorder Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Generalized Anxiety Disorder Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Generalized Anxiety Disorder Market drivers<\/p>\n<p style=\"text-align: justify;\">16. Generalized Anxiety Disorder Market barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Generalized Anxiety Disorder Appendix<\/p>\n<p style=\"text-align: justify;\">18. Generalized Anxiety Disorder Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Generalized Anxiety Disorder treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/generalized-anxiety-disorder-gad-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Generalized Anxiety Disorder Medications<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=generalized-anxiety-disorder-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-takeda-astrazeneca-eli-lilly-and-company-forest-laboratories\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=generalized-anxiety-disorder-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-takeda-astrazeneca-eli-lilly-and-company-forest-laboratories\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s \u201cGeneralized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Generalized Anxiety Disorder, historical and forecasted epidemiology as well as the Generalized Anxiety Disorder market trends in the United States, EU5 (Germany, Spain, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/generalized-anxiety-disorder-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-takeda-astrazeneca-eli-lilly-and-company-forest-laboratories_616077.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[447,405,417,406,423],"tags":[],"class_list":["post-616077","post","type-post","status-publish","format-standard","hentry","category-Education","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/616077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=616077"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/616077\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=616077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=616077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=616077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}